Lamotrigine Extended Release 250 mg/1
lamotrigine extended release · TABLET · Par Health USA, LLC
Lamotrigine Extended Release is a prescription tablet used to treat seizures in epilepsy and to help prevent mood episodes in bipolar disorder. This medication is an anti-epileptic agent that works by stabilizing electrical activity in the brain.
Key Facts
- Brand Name
- Lamotrigine Extended Release
- Generic Name
- lamotrigine extended release
- NDC Code (Product)
49884-604- Manufacturer
- Par Health USA, LLC
- Strength
- 250 mg/1
- Dosage Form
- TABLET
- Route
- ORAL
- Marketing Status
- Application #
- ANDA201791
- Drug Class
- Anti-epileptic Agent [EPC]; Mood Stabilizer [EPC]
- Marketing Start
- 01/18/2013
Recall History
Wockhardt Usa Inc.
CGMP Deviations: Firm did not adequately investigate customer complaints.
Cardinal Health Inc.
CGMP Deviations: Intermittent exposure to temperature excursion during storage.
Torrent Pharma Inc.
Failed Dissolution Specifications: Out of Specification for Dissolution test (Buffer Stage) at the 5-hour time point during stability testing.
Frequently Asked Questions
What is Lamotrigine Extended Release used for?
Lamotrigine Extended Release is a prescription tablet used to treat seizures in epilepsy and to help prevent mood episodes in bipolar disorder. This medication is an anti-epileptic agent that works by stabilizing electrical activity in the brain.
Is Lamotrigine Extended Release a controlled substance?
Lamotrigine Extended Release is not classified as a controlled substance by the DEA.
What is the generic name for Lamotrigine Extended Release?
The generic name for Lamotrigine Extended Release is lamotrigine extended release. There are no other listed brand versions of lamotrigine extended release.
What is the NDC code for Lamotrigine Extended Release 250 mg/1?
The NDC (National Drug Code) for Lamotrigine Extended Release 250 mg/1 is 49884-604, listed by Par Health USA, LLC.
Other Lamotrigine Extended Release Dosages
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)